Entera Bio Ltd (ENTX) Return on Assets ROA from the second quarter of 2026 to second quarter of 2025 and for the year 2026, Average High and Low, Fundamental Ratios from Jun 30 2026 to Jun 30 2025 - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Entera Bio Ltd   (NASDAQ: ENTX)


Entera Bio Ltd 's ROA from the second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics


What is Entera Bio Ltd 's ROA in the second quarter of 2026?
Entera Bio Ltd achieved a return on average assets (ROA) of 10 % in its second quarter of 2026, which is below Entera Bio Ltd 's average return on assets, which stands at 35.08%.

ROA decreased relative to the period ending Mar 31 2026, due to the decline in net income.

However, within the Healthcare sector 68 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Jun 30 2026 quarter, so far to 48, from total ROA ranking in the first quarter of 2026 at 74.

What is ROA?


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Assets (Jun 30 2026)
II. Quarter		 (Mar 31 2026)
I. Quarter		 (Dec 31 2025)
IV. Quarter		 (Sep 30 2025)
III. Quarter		 (Jun 30 2025)
II. Quarter
Y / Y Total Assets Change -2.79 % -39.22 % 55.51 % 122.62 % 101.61 %
Y / Y Net Income Change - 36.54 % - 5.93 % -
Net Income (TTM) in million 2 12 11 6 6
Return On Assets (TTM) 10 % 51.1 % 43.43 % 27.35 % 29.76 %
ENTX's Total Ranking # 48 # 74 # 124 # 96 # 701
Total Assets (TTM) in million 19 13 47 17 20
Seq. Total Assets Change 45.62 % -71.87 % 168.16 % -11.49 % -8.95 %
Seq. Net Income Change - 16.21 % -5.75 % 20.48 % 3.47 %

ENTX's 5 Years Annual ROA >> Back to ENTX Management Effectiveness >> Compare ENTX ROA to its Competitors


Return On Assets Company Ranking
Within: No.
Industry # 15
Sector # 69
Overall # 365

Return On Assets Statistics
High Average Low
85.01 %
35.08 %
-39.6 %
(Mar 31 2024)   (Dec 31 2022)





Financial Statements
Entera Bio Ltd 's Assets $ 19 million ENTX's Balance sheet
Entera Bio Ltd 's Income $ -7 million Quarterly ENTX's Income Statement
ENTX's Income by Division See ENTX's Income by Division



Annual Return On Assets (Dec 31 2025)
FY 2025		 (Dec 31 2024)
FY 2024		 (Dec 31 2023)
FY 2023		 (Dec 31 2022)
FY 2022		 (Dec 31 2021)
FY 2021
Y / Y Total Assets Change 55.51 % -4.83 % 1.31 % -24.22 % 33.5 %
Total Assets in million 47 30 32 31 41
Y / Y Net Income Change 19.89 % 7.33 % -31.99 % 7.25 % -
Net Income in million 11 10 9 13 12
Annual Return On Assets 24.51 % 31.79 % 28.18 % 41.98 % 29.66 %

ENTX's 5 Years Annual ROA >> Back to ENTX Management Effectiveness >> Compare ENTX ROA to its Competitors



Comment on ENTX's ROA in the fiscal year ending 2025
In the fiscal year 2025 ROA deteriorated to 24.51 %, despite annual net income growth of 19.89 % to $11.44 million, from $9.54 million a year ago, as ENTX's assets increase to $46.68 million, by 19.89 %.


More Return On Assets Ratios
ENTX's' Return on Assets at Yahoo Finance
Biotechnology & Pharmaceuticals Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
ENTX's Roa Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for ENTX's Competitors
Subscribers only: Roa for Entera Bio Ltd 's Suppliers
Subscribers only: Return On Assets for ENTX's Customers

You may also want to know
ENTX's Roi ENTX's Inventory Turnover Ratio ENTX's Growth Rates ENTX's Dividend Comparisons
ENTX's Profitability Ratios ENTX's Asset Turnover Ratio ENTX's Dividend Growth
ENTX's Roe ENTX's Valuation Ratios ENTX's Financial Strength Ratios ENTX's Dividend Payout Ratio



Companies with similar Return On Assets at Jun 30 2026, within Healthcare Sector ROA
Qhslab Inc   27.12 %
Adma Biologics Inc   26.58 %
Mettler toledo International Inc   24.86 %
Medpace Holdings Inc   24.84 %
Caredx Inc   24.81 %
Acadia Pharmaceuticals Inc   24.38 %
Eli Lilly And Company  21.97 %
Innoviva Inc   21.64 %
Vaxart Inc   20.85 %
Zevra Therapeutics Inc   20.39 %
Iradimed Corporation  20.36 %
Protalix Biotherapeutics inc   20.09 %
Pro dex Inc   19.87 %
Electromed Inc   19.39 %
United Therapeutics Corporation  17.98 %
Resmed Inc   17.80 %
Krystal Biotech Inc   17.65 %
Chemed Corporation  17.52 %
Zoetis Inc   17.19 %
Vertex Pharmaceuticals Inc  16.88 %
Halozyme Therapeutics Inc   16.55 %
Alnylam Pharmaceuticals Inc   15.76 %
Intuitive Surgical Inc   15.63 %
Healthcare Services Group Inc   15.21 %
Inspire Medical Systems inc   15.21 %
Dexcom Inc   14.87 %
Neurocrine Biosciences Inc   14.73 %
Entera Bio Ltd   14.60 %
Standard Biotools Inc   14.31 %
Arcutis Biotherapeutics Inc   14.23 %

Date modified: 2026-08-14T19:56:43+00:00


Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.